Drug intelligence / Profile preview

bacillus subtilis + bacillus clausii

Development stage: Unknown
Lead developer: LiveSpo Pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bacillus subtilis + bacillus clausii is a probiotic combination consisting of two spore-forming, Gram-positive bacterial species. These bacteria are characterized by their ability to form endospores, which provides significant resistance to environmental stressors such as heat, gastric acidity, and bile salts, ensuring high viability upon reaching the intestines. The combination works by restoring the balance of the intestinal microbiota, competing with pathogenic bacteria for nutrients and adhesion sites (competitive exclusion), and producing antimicrobial substances like bacteriocins. Additionally, these strains modulate the host immune system by interacting with gut-associated lymphoid tissue (GALT). It is primarily used for the management of gastrointestinal disorders, including acute diarrhea, antibiotic-associated diarrhea, and inflammatory bowel conditions.

Other names: Bacillus subtilis and Bacillus clausii combinationBacillus subtilis/Bacillus clausii

Beyond the preview

Go deeper on bacillus subtilis + bacillus clausii.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bacillus subtilis + bacillus clausii.

Explore the full profile